Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Endocrine
Erschienen in: Endocrine 2/2012

01.10.2012 | Mini Review

PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas

verfasst von: Hadara Rubinfeld, Ilan Shimon

Erschienen in: Endocrine | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Non-functioning pituitary adenomas (NFPAs) comprise a heterogeneous group, which are considered the most common pituitary tumor. As no clinically hormone hypersecretion is apparent, non-functioning pituitary adenomas are often diagnosed only when they are large enough to cause tumor mass effects, such as hypopituitarism, visual field defects or headaches. Efficient medical therapy for NFPAs is currently unavailable and surgical treatment of these tumors is not always satisfactory. Characterization of signaling regulatory events in the context of NFPAs may enable the development of new attractive novel strategies. Although data regarding gene expression profiling of signaling pathways in NFPAs have accumulated, studies aimed at fine-classification of NFPAs-specific signaling regulatory mechanisms and feedback loops are scarce.
Literatur
1.
F. Roelfsema, N.R. Biermasz, A.M. Pereira, Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15, 71–83 (2011)CrossRef
2.
A. Colao, C. Di Somma, R. Pivonello, A. Faggiano, G. Lombardi, S. Savastano, Medical therapy for clinically non-functioning pituitary adenomas. Endocr. Relat. Cancer 15(4), 905–915 (2008)PubMedCrossRef
3.
M.A. Tichomirowa, A.F. Daly, A. Beckers, Treatment of pituitary tumors: somatostatin. Endocrine 28(1), 93–100 (2005)PubMedCrossRef
4.
A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, B. Dipl, D. Mills, L.R. Salgado, B.M. Biller, A 12-month phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med. 366(10), 914–924 (2012)PubMedCrossRef
5.
M. Boscaro, W.H. Ludlam, B. Atkinson, J.E. Glusman, S. Petersenn, M. Reincke, P. Snyder, A. Tabarin, B.M. Biller, J. Findling, S. Melmed, C.H. Darby, K. Hu, Y. Wang, P.U. Freda, A.B. Grossman, L.A. Frohman, J. Bertherat, Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J. Clin. Endocrinol. Metab. 94(1), 115–122 (2009)PubMedCrossRef
6.
M.S. Elston, A.J. Gill, J.V. Conaglen, A. Clarkson, J.M. Shaw, A.J. Law, R.J. Cook, N.S. Little, R.J. Clifton-Bligh, B.G. Robinson, K.L. McDonald, Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology 149(3), 1235–1242 (2008)PubMedCrossRef
7.
N.A. Hibberts, D.J. Simpson, J.E. Bicknell, J.C. Broome, P.R. Hoban, R.N. Clayton, W.E. Farrell, Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin. Cancer Res. 5(8), 2133–2139 (1999)PubMed
8.
S. Jordan, K. Lidhar, M. Korbonits, D.G. Lowe, A.B. Grossman, Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur. J. Endocrinol. 143(1), R1–R6 (2000)PubMedCrossRef
9.
D.J. Simpson, S.J. Frost, J.E. Bicknell, J.C. Broome, A.M. McNicol, R.N. Clayton, W.E. Farrell, Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 22(8), 1149–1154 (2001)PubMedCrossRef
10.
H.E. Turner, Z. Nagy, N. Sullivan, M.M. Esiri, J.A. Wass, Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin. Endocrinol. (Oxf) 53(3), 337–344 (2000)CrossRef
11.
V. Chesnokova, S. Zonis, C. Zhou, A. Ben-Shlomo, K. Wawrowsky, Y. Toledano, Y. Tong, K. Kovacs, B. Scheithauer, S. Melmed, Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One 6(3), e17924 (2011)PubMedCrossRef
12.
G.M. Pierantoni, P. Finelli, E. Valtorta, D. Giardino, O. Rodeschini, F. Esposito, M. Losa, A. Fusco, L. Larizza, High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. Endocr. Relat. Cancer 12(4), 867–874 (2005)PubMedCrossRef
13.
C.S. Moreno, C.O. Evans, X. Zhan, M. Okor, D.M. Desiderio, N.M. Oyesiku, Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res. 65(22), 10214–10222 (2005)PubMedCrossRef
14.
X. Zhang, Y. Zhou, K.R. Mehta, D.C. Danila, S. Scolavino, S.R. Johnson, A. Klibanski, A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J. Clin. Endocrinol. Metab. 88(11), 5119–5126 (2003)PubMedCrossRef
15.
J. Zhao, D. Dahle, Y. Zhou, X. Zhang, A. Klibanski, Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J. Clin. Endocrinol. Metab. 90(4), 2179–2186 (2005)PubMedCrossRef
16.
K.J. Dudley, K. Revill, R.N. Clayton, W.E. Farrell, Pituitary tumours: all silent on the epigenetics front. J. Mol. Endocrinol. 42(6), 461–468 (2009)PubMedCrossRef
17.
D.A. Altomare, J.R. Testa, Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50), 7455–7464 (2005)PubMedCrossRef
18.
I. Vivanco, C.L. Sawyers, The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2(7), 489–501 (2002)PubMedCrossRef
19.
Y. Lin, X. Jiang, Y. Shen, M. Li, H. Ma, M. Xing, Y. Lu, Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr. Relat. Cancer 16(1), 301–310 (2009)PubMedCrossRef
20.
M. Musat, M. Korbonits, B. Kola, N. Borboli, M.R. Hanson, A.M. Nanzer, J. Grigson, S. Jordan, D.G. Morris, M. Gueorguiev, M. Coculescu, S. Basu, A.B. Grossman, Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr. Relat. Cancer 12(2), 423–433 (2005)PubMedCrossRef
21.
M. Xu, L. Shorts-Cary, A.J. Knox, B. Kleinsmidt-DeMasters, K. Lillehei, M.E. Wierman, Epidermal growth factor receptor pathway substrate 8 is overexpressed in human pituitary tumors: role in proliferation and survival. Endocrinology 150(5), 2064–2071 (2009)PubMedCrossRef
22.
D. Dworakowska, E. Wlodek, C.A. Leontiou, S. Igreja, M. Cakir, M. Teng, N. Prodromou, M.I. Goth, S. Grozinsky-Glasberg, M. Gueorguiev, B. Kola, M. Korbonits, A.B. Grossman, Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr. Relat. Cancer 16(4), 1329–1338 (2009)PubMedCrossRef
23.
U. Pagotto, T. Arzberger, M. Theodoropoulou, Y. Grubler, C. Pantaloni, W. Saeger, M. Losa, L. Journot, G.K. Stalla, D. Spengler, The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res. 60(24), 6794–6799 (2000)PubMed
24.
T.W. Noh, H.J. Jeong, M.K. Lee, T.S. Kim, S.H. Kim, E.J. Lee, Predicting recurrence of nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 94(11), 4406–4413 (2009)PubMedCrossRef
25.
M. Theodoropoulou, G.K. Stalla, D. Spengler, ZAC1 target genes and pituitary tumorigenesis. Mol. Cell. Endocrinol. 326(1–2), 60–65 (2010)PubMedCrossRef
26.
27.
A. Perren, P. Komminoth, P. Saremaslani, C. Matter, S. Feurer, J.A. Lees, P.U. Heitz, C. Eng, Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. J. Pathol. 157(4), 1097–1103 (2000)PubMedCrossRef
28.
M.L. Tena-Suck, A. Ortiz-Plata, H.A. de la Vega, Phosphatase and tensin homologue and pituitary tumor-transforming gene in pituitary adenomas. Clinical-pathologic and immunohistochemical analysis. Ann. Diagn. Pathol. 12(4), 275–282 (2008)PubMedCrossRef
29.
V. Vasko, M. Saji, E. Hardy, M. Kruhlak, A. Larin, V. Savchenko, M. Miyakawa, O. Isozaki, H. Murakami, T. Tsushima, K.D. Burman, C. De Micco, M.D. Ringel, Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J. Med. Genet. 41(3), 161–170 (2004)PubMedCrossRef
30.
A.M. Martelli, I. Faenza, A.M. Billi, L. Manzoli, C. Evangelisti, F. Fala, L. Cocco, Intranuclear 3′-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell. Signal. 18(8), 1101–1107 (2006)PubMedCrossRef
31.
L.C. Trotman, A. Alimonti, P.P. Scaglioni, J.A. Koutcher, C. Cordon-Cardo, P.P. Pandolfi, Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441(7092), 523–527 (2006)PubMedCrossRef
32.
S.S. Chaidarun, M.C. Eggo, M.C. Sheppard, P.M. Stewart, Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology 135(5), 2012–2021 (1994)PubMedCrossRef
33.
V.K. LeRiche, S.L. Asa, S. Ezzat, Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J. Clin. Endocrinol. Metab. 81(2), 656–662 (1996)PubMedCrossRef
34.
M.L. Jaffrain-Rea, E. Petrangeli, C. Lubrano, G. Minniti, D. Di Stefano, F. Sciarra, L. Frati, G. Tamburrano, G. Cantore, A. Gulino, Epidermal growth factor binding sites in human pituitary macroadenomas. J. Endocrinol. 158(3), 425–433 (1998)PubMedCrossRef
35.
A. Rishi, M.C. Sharma, C. Sarkar, D. Jain, M. Singh, A.K. Mahapatra, V.S. Mehta, T.K. Das, A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience. Neurol. India 58(3), 418–423 (2010)PubMedCrossRef
36.
M. Theodoropoulou, T. Arzberger, Y. Gruebler, M.L. Jaffrain-Rea, J. Schlegel, L. Schaaf, E. Petrangeli, M. Losa, G.K. Stalla, U. Pagotto, Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J. Endocrinol. 183(2), 385–394 (2004)PubMedCrossRef
37.
O. Cooper, G. Vlotides, H. Fukuoka, M.I. Greene, S. Melmed, Expression and function of ErbB receptors and ligands in the pituitary. Endocr. Relat. Cancer 18(6), R197–R211 (2011)PubMedCrossRef
38.
P.P. Di Fiore, G. Scita, Eps8 in the midst of GTPases. Int. J. Biochem. Cell Biol. 34(10), 1178–1183 (2002)PubMedCrossRef
39.
F. Fazioli, L. Minichiello, V. Matoska, P. Castagnino, T. Miki, W.T. Wong, P.P. Di Fiore, Eps8, a substrate for the epidermal growth factor receptor kinase, enhances EGF-dependent mitogenic signals. EMBO J. 12(10), 3799–3808 (1993)PubMed
40.
M. Innocenti, E. Frittoli, I. Ponzanelli, J.R. Falck, S.M. Brachmann, P.P. Di Fiore, G. Scita, Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1. J. Cell Biol. 160(1), 17–23 (2003)PubMedCrossRef
41.
Y. Greenman, S. Melmed, Diagnosis and management of nonfunctioning pituitary tumors. Annu. Rev. Med. 47, 95–106 (1996)PubMedCrossRef
42.
I. Ewing, S. Pedder-Smith, G. Franchi, M. Ruscica, M. Emery, V. Vax, E. Garcia, S. Czirjak, Z. Hanzely, B. Kola, M. Korbonits, A.B. Grossman, A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin. Endocrinol (Oxf) 66(3), 348–352 (2007)CrossRef
43.
T.W. de Bruin, D.J. Kwekkeboom, J.W. Van’t Verlaat, J.C. Reubi, E.P. Krenning, S.W. Lamberts, R.J. Croughs, Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J. Clin. Endocrinol. Metab. 75(5), 1310–1317 (1992)PubMedCrossRef
44.
M. Gasperi, L. Petrini, R. Pilosu, M. Nardi, A. Marcello, F. Mastio, L. Bartalena, E. Martino, Octreotide treatment does not affect the size of most non-functioning pituitary adenomas. J. Endocrinol. Invest. 16(7), 541–543 (1993)PubMed
45.
T. Florio, S. Thellung, S. Arena, A. Corsaro, R. Spaziante, G. Gussoni, G. Acuto, M. Giusti, G. Giordano, G. Schettini, Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur. J. Endocrinol. 141(4), 396–408 (1999)PubMedCrossRef
46.
H. Padova, H. Rubinfeld, M. Hadani, Z.R. Cohen, D. Nass, J.E. Taylor, M.D. Culler, I. Shimon, Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas. Mol. Cell. Endocrinol. 286(1–2), 214–218 (2008)PubMedCrossRef
47.
U. Renner, J. Mojto, M. Lange, O.A. Muller, K. von Werder, G.K. Stalla, Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro. Eur. J. Endocrinol. 130(1), 80–91 (1994)PubMedCrossRef
48.
M.C. Zatelli, D. Piccin, C. Vignali, F. Tagliati, M.R. Ambrosio, M. Bondanelli, V. Cimino, A. Bianchi, H.A. Schmid, M. Scanarini, A. Pontecorvi, L. De Marinis, G. Maira, E.C. degli Uberti, Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr. Relat. Cancer 14(1), 91–102 (2007)PubMedCrossRef
49.
E. Hubina, A.M. Nanzer, M.R. Hanson, E. Ciccarelli, M. Losa, D. Gaia, M. Papotti, M.R. Terreni, S. Khalaf, S. Jordan, S. Czirjak, Z. Hanzely, G.M. Nagy, M.I. Goth, A.B. Grossman, M. Korbonits, Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur. J. Endocrinol. 155(2), 371–379 (2006)PubMedCrossRef
50.
M. Theodoropoulou, J. Zhang, S. Laupheimer, M. Paez-Pereda, C. Erneux, T. Florio, U. Pagotto, G.K. Stalla, Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 66(3), 1576–1582 (2006)PubMedCrossRef
51.
T. Florio, F. Barbieri, R. Spaziante, G. Zona, L.J. Hofland, P.M. van Koetsveld, R.A. Feelders, G.K. Stalla, M. Theodoropoulou, M.D. Culler, J. Dong, J.E. Taylor, J.P. Moreau, A. Saveanu, G. Gunz, H. Dufour, P. Jaquet, Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr. Relat. Cancer 15(2), 583–596 (2008)PubMedCrossRef
52.
E. Peverelli, L. Olgiati, M. Locatelli, P. Magni, M.F. Fustini, G. Frank, G. Mantovani, P. Beck-Peccoz, A. Spada, A. Lania, The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Lett. 288(2), 170–176 (2010)PubMedCrossRef
53.
P. Luciani, S. Gelmini, E. Ferrante, A. Lania, S. Benvenuti, S. Baglioni, G. Mantovani, I. Cellai, F. Ammannati, A. Spada, M. Serio, A. Peri, Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 90(11), 6156–6161 (2005)PubMedCrossRef
54.
M. Korbonits, E. Carlsen, Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm. Res. 71(Suppl 2), 123–130 (2009)PubMedCrossRef
55.
V. Cerovac, J. Monteserin-Garcia, H. Rubinfeld, M. Buchfelder, M. Losa, T. Florio, M. Paez-Pereda, G.K. Stalla, M. Theodoropoulou, The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res. 70(2), 666–674 (2010)PubMedCrossRef
56.
M. Breuleux, M. Klopfenstein, C. Stephan, C.A. Doughty, L. Barys, S.M. Maira, D. Kwiatkowski, H.A. Lane, Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol. Cancer Ther. 8(4), 742–753 (2009)PubMedCrossRef
57.
A. Gorshtein, H. Rubinfeld, E. Kendler, M. Theodoropoulou, V. Cerovac, G.K. Stalla, Z.R. Cohen, M. Hadani, I. Shimon, Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr. Relat. Cancer 16(3), 1017–1027 (2009)PubMedCrossRef
58.
M.C. Zatelli, M. Minoia, C. Filieri, F. Tagliati, M. Buratto, M.R. Ambrosio, M. Lapparelli, M. Scanarini, E.C. Degli Uberti, Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 95(2), 968–976 (2010)PubMedCrossRef
59.
K.E. O’Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, D. Smith, H. Lane, F. Hofmann, D.J. Hicklin, D.L. Ludwig, J. Baselga, N. Rosen, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66(3), 1500–1508 (2006)PubMedCrossRef
60.
M. Lee, M. Theodoropoulou, J. Graw, F. Roncaroli, M.C. Zatelli, N.S. Pellegata, Levels of p27 sensitize to dual PI3K/mTOR inhibition. Mol. Cancer Ther. 10(8), 1450–1459 (2011)PubMedCrossRef
61.
B. Kola, M. Korbonits, S. Diaz-Cano, G. Kaltsas, D.G. Morris, S. Jordan, L. Metherell, M. Powell, S. Czirjak, G. Arnaldi, S. Bustin, M. Boscaro, F. Mantero, A.B. Grossman, Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clin. Endocrinol (Oxf) 59(3), 328–338 (2003)CrossRef
62.
H. Rubinfeld, A. Gorshtein, E. Kendler, A. Kamar, O. Cohen, M. Hadani, I. Shimon IGF-1 induces tumorigenesis in human pituitary tumors—functional blockade of IGF-1 receptor as a novel therapeutic approach in non-functioning tumors, in 2nd ENEA Workshop, Aggressive Pituitary Tumors, Munich, 2011, p. 71
63.
F.M. Sirotnak, M.F. Zakowski, V.A. Miller, H.I. Scher, M.G. Kris, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6(12), 4885–4892 (2000)PubMed
64.
H. Fukuoka, O. Cooper, J. Mizutani, Y. Tong, S.G. Ren, S. Bannykh, S. Melmed, HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol. Endocrinol. 25(1), 92–103 (2011)PubMedCrossRef
65.
G. Vlotides, E. Siegel, I. Donangelo, S. Gutman, S.G. Ren, S. Melmed, Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res. 68(15), 6377–6386 (2008)PubMedCrossRef
66.
U. Kumar, Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine 40(2), 168–180 (2011)PubMedCrossRef
67.
X. Shi, B. Tao, H. He, Q. Sun, C. Fan, L. Bian, W. Zhao, Y.C. Lu, MicroRNAs-based network: a novel therapeutic agent in pituitary adenoma. Med. Hypotheses 78(3), 380–384 (2012)PubMedCrossRef
68.
X. Zhan, D.M. Desiderio, Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med. Genomics 3, 13 (2010)PubMedCrossRef
Metadaten
Titel
PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas
verfasst von
Hadara Rubinfeld
Ilan Shimon
Publikationsdatum
01.10.2012
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2012
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9682-3

Weitere Artikel der Ausgabe 2/2012

Endocrine 2/2012 Zur Ausgabe

Original Article

Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women

Original Article

Biomechanical properties of the mid-shaft femur in middle-aged hypophysectomized rats as assessed by bending test

Original Article

Expression of cholecystokinin-1 receptor is correlated with proteinuria in human diabetic nephropathy

Editorial

Bone and hypopituitarism: not only a mass issue

Original Article

Increased high-density lipoprotein cholesterol is associated with a high prevalence of pre-hypertension and hypertension in community-dwelling persons

Original Article

Determining cut-off values for neck circumference as a measure of the metabolic syndrome amongst a South African cohort: the SABPA study

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise